Conba announced that its wholly-owned subsidiary Inner Mongolia Conba has received a Drug Clinical Trial Approval Notice for Shexiang Tongxin Dropping Pills from the National Medical Products Administration, granting permission to conduct a clinical trial for heart failure with preserved ejection fraction, classified as Qi deficiency and blood stasis syndrome. The drug is registered as a Category 2.3 traditional Chinese medicine, representing an expansion of therapeutic indications. Shexiang Tongxin Dropping Pills are an exclusive traditional Chinese medicine variety of the company in China and a national second-class protected traditional Chinese medicine variety. They were approved for marketing in 2008, with the previously approved indication being stable exertional angina pectoris in coronary heart disease.
Zhejiang CONBA Pharmaceutical Co LtdClinical trial approval for new indication expands therapeutic use of exclusive drug.